Study of the efficacy of Ceftaroline in the management of pediatric severe sepsis and septic shock

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202404502445612

Enrollment

Registered

2024-04-22

Start date

2022-11-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Paediatrics

Interventions

Ceftaroline

Third generation Cephalosporin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe sepsis or septic shock as defined by The Surviving Sepsis Campaign (SSC) guidelines 2020.

Exclusion criteria

Exclusion criteria: - Severe immunodeficiency patients (congenital or acquired). - Malignancies and patients receiving chemotherapy. - Hypersensitivity to any active substances of the drug. - Cases that received Ceftaroline prior to admission

Design outcomes

Primary

Measure	Time frame
C-reactive protein CRP blood level;Negative Blood CSF Urine Pleural cultures results	—

Secondary

Measure	Time frame
Length of Pediatric Intensive Care Unit stay;Number of Days of Therapy	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026